5-Azacytidine carcinogenesis in BALB/c mice.
5-Azacytidine, a drug used in the treatment of acute leukaemias and beta-thalassemia, was administered i.p. to BALB/c mice at a dose of 2.0 mg/kg body wt. once a week for 50 weeks to test its carcinogenicity. The treatment induced a significant increase in lung tumours (males P less than 0.001, females P less than 0.05), lymphomas (males P less than 0.01, females P less than 0.01), skin tumours (males P less than 0.05, females P less than 0.01) in both sexes and mammary carcinomas (P less than 0.01) and a variety of other tumours in female mice. These results, with other investigations reported in literature, suggest that 5-azacytidine is carcinogenic in mice.
D000818:Animals; D001374:Azacitidine / Q000633:toxicity*; D002273:Carcinogens; D005260:Female; D008175:Lung Neoplasms / Q000139:chemically induced; D008223:Lymphoma / Q000139:chemically induced; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D051379:Mice; D008807:Mice, Inbred BALB C; D012878:Skin Neoplasms / Q000139:chemically induced
D002273:Carcinogens; D001374:Azacitidine